Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):61-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti

 

ORIGINAL ARTICLES  NEUROENDOCRINE UPDATE AND METABOLIC THERAPY 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):61-7

Copyright © 2010 EDIZIONI MINERVA MEDICA

lingua: Inglese

Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions

Prasad V., Baum R. P.

Department of Nuclear Medicine/Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany


PDF


AIM: The aim of the study was 1) to determine the normal biodistribution of radiolabeled somatostatin analogue 68Ga DOTA-NOC; 2) to establish the range of its uptake in liver, bone and lymph node metastases in patients with NET, 3) to establish the cut-off value for differentiating between physiological uptake and tumor related sstr expression in the processus uncinatus of pancreas.
METHODS: Maximum standardized uptake values (SUVmax) of 68Ga DOTA-NOC were determined in normal organs of 89 NET patients undergoing receptor PET/CT. In addition, SUVmax of primary pancreatic neuroendocrine tumors (pNET), liver, bone and lymph node metastases were evaluated.
RESULTS: SUVmax (mean±standard deviation) were determined in: pituitary gland 2.6±1.3, thyroid: 3.4±1.4, lung: 0.9±0.8, normal liver: 6.9±2 , spleen: 22.0±10.0, adrenal 6.0±2.5, kidney: 12.9±3.8, gastrointestinal tract 2.3±1.0, gluteal muscle:1.0±0.3, femur 0.8±0.3, blood pool 2.6± 1.2 and processus uncinatus of pancreas 5.8±2.0. SUVmax of 68Ga DOTA-NOC was 19.6±13.4 (N.=200) in liver metastases, 12.5±10 (N.=67) in lymph nodes metastasis, 9.5±6.0 (N.=78) in bone lesions, and 20.8±10.8 (N.=26) in pancreatic neuroendocrine primary tumors. Target to non target (T/NT) ratios were 3.4±2.3 for liver metastases (with normal CONCLUSIONS: There is a broad range of sstr expression in metastastic lesions and in pNET. The splenic uptake of 68Ga DOTA-NOC is highly variable. 68Ga DOTA-NOC is an excellent tracer for imaging somatostatin receptor positive tumors, which, due to the high target to non-target ratios, allows the detection of very small lesions, especially of lymph node and bone metastases.

inizio pagina